Topics In Demand
Notification
New

No notification found.

Transforming Healthcare with Generative AI: Emerging Use Cases and Future Possibilities
Transforming Healthcare with Generative AI: Emerging Use Cases and Future Possibilities

536

0

In the dynamic realm of healthcare and wellness, a revolution is underway as ANI meets Generative AI, opening up new frontiers and possibilities in the medical landscape. The emerging use cases of Generative AI in the healthcare industry are rapidly reshaping medical research, diagnostics, and treatment approaches, thus offering unparalleled potential for personalized patient care and revolutionizing drug discovery & development processes.

GENERATIVE AI USE CASES IN HEALTHCARE

Source:  Emorphis Health

These use cases can be classified into six major segments. With companies seeking to unlock maximum value from Gen AI in novel ways, continuous developments are taking place across all the segments.

 

Healthcare Providers

 

Generative AI is making significant strides in the healthcare industry, and providers are at the forefront of leveraging its potential. Some products already on the market showcase the power of this technology. Paige.AI, a digital pathology company, has integrated Generative AI to enhance prostate cancer detection accuracy and efficiency, setting a precedent for FDA approval in digital pathology. On the administrative front, companies like Doximity, Abridge, and DeepScribe are exploring solutions for automating documentation, claims handling, and patient onboarding, streamlining healthcare operations.

With advancements in gen AI picking up pace, some other providers have also started exploring digital solutions that enable patient interactions. A good example is Babylon Health's digital health service, that utilizes Generative AI to understand patients’ evolving risk profile, and offers personalized care at reduced costs. Additionally, Serena's generative AI-powered counseling chatbot delivers accessible mental health care on-demand.

In the future, Generative AI is poised to revolutionize real-time patient monitoring, offering personalized insights for healthier behaviors and timely interventions. Enhanced imaging solutions and adaptive technologies could encourage preventive care and wellness through tailored nudges on mobile apps, wearables, and monitoring devices.

 

Pharmaceutical Companies

 

Pharmaceutical firms are witnessing remarkable advancements with Generative AI. For instance, Insilico Medicine's accelerated drug discovery process shortened their time from novel-target discovery to preclinical candidate to just 18 months at cost of only $2.6 million, highlighting the immense potential of this technology. The company’s drug for idiopathic pulmonary fibrosis got the Orphan Drug Designation from the FDA in just 30 months. Exscientia’s use of Gen AI for analysis of patient tissue and employment of functional precision oncology is another good example. NVIDIA's generative AI cloud services are also accelerating drug discovery and research in genomics, chemistry, biology, and molecular dynamics.

In conjunction to this, some early-stage and conceptual use cases are also presenting exciting opportunities for drug development. Biotech firms like Ordaōs, Absci, and Profluent are utilizing Generative AI to design innovative miniproteins, antibodies, and protein sequences respectively, thereby paving the way for rare cancer treatments and immune disease therapies. Synthesized is helping researchers in expanding the use of existing drugs to a wider range of diseases. Recently, digital modeling of clinical trials (including synthetic control groups) also got validation.

Going forward, Generative AI is poised to revolutionize preclinical and clinical stages, enabling faster access to therapeutics, even for challenging rare conditions. Personalized drug treatments and subgroup responsiveness analysis could become a reality, ushering in a new era of precision medicine.

 

Payers (Insurers)

 

Payers are recognizing the potential of Generative AI to enhance cost-efficiency and member engagement. Validated products, like DigitalOwl's solution for automation of underwriting and claims management processes, are driving affordability and streamlined operations. On the other hand, companies like ConcertAI are developing predictive models (currently in early stage) based on Generative AI to proactively manage high-risk segments by leveraging patient history and social determinants of health.

Looking ahead, Generative AI could revolutionize payer applications with conversational AI delivering personalized health messages based on member preferences, leading to improved member engagement.

 

Medtech Companies

 

The medtech industry is embracing Generative AI to create personalized and patient-centered devices, ushering in a new era of preventive maintenance and improved patient experiences. For instance, the UK's National Centre for Additive Manufacturing is optimizing medical device designs such as prosthetics and implants, tailored to individual patients. While medtech company Implicity is leveraging the technology to incorporate remote monitoring in pacemakers and implantable defibrillators, DiagnaMed's generative AI-driven platform for brain health analysis holds great promise for mental health and neurodegenerative disorders. The company’s Gen AI platform analyses electroencephalography signals to predict and monitor brain aging and aids in diagnosis, prevention, or mitigation of cognitive decline in patients.

In the future, Generative AI applications could enable more effective patient interventions through remote monitoring systems and accurate quality control predictions for medical devices, minimizing downtime and enhancing patient care.

 

Services and Operations

 

Generative AI is making significant contributions to healthcare services by optimizing data analytics, and software operations for more flexible and interoperable applications. Innovative companies like Syntegra and Google's EHR-Safe are generating synthetic health care datasets, offering invaluable insights for public health programs. If innovation at this pace continues, Generative AI-powered tools may transform health systems by optimizing inventory tracking, data sharing, HR functions, and corporate applications, thus driving efficiency and personalization.

 

Public-Health Agencies

 

Public-health agencies and government organizations are harnessing Generative AI to enhance resource planning and allocation, anticipate public-health needs, and execute programs effectively. Early-stage and conceptual examples include BioNTech's acquisition of InstaDeep to develop an early-warning system for new COVID-19 variants. The system is designed to proactively alert relevant stakeholders such as researchers, vaccine developers, health authorities, and policymakers.

In years to come, Generative AI is expected to revolutionize public-health monitoring and resource allocation, enabling more effective decision-making processes. From Medicaid to the FDA, public-health groups may leverage Generative AI to optimize health data management and predict outbreaks, thus minimizing their impact on society.

 

Outlook

 

Generative AI is poised to revolutionize the healthcare industry by offering unprecedented potential in areas ranging from drug discovery and precision medicine to patient care and resource management. As we explore the emerging use cases and future prospects of Generative AI, it becomes clear that this technology will play a transformative role in advancing healthcare and improving patient outcomes. With ongoing advancements, we can expect a future where Generative AI becomes an indispensable ally in our collective journey towards better health and well-being.


That the contents of third-party articles/blogs published here on the website, and the interpretation of all information in the article/blogs such as data, maps, numbers, opinions etc. displayed in the article/blogs and views or the opinions expressed within the content are solely of the author's; and do not reflect the opinions and beliefs of NASSCOM or its affiliates in any manner. NASSCOM does not take any liability w.r.t. content in any manner and will not be liable in any manner whatsoever for any kind of liability arising out of any act, error or omission. The contents of third-party article/blogs published, are provided solely as convenience; and the presence of these articles/blogs should not, under any circumstances, be considered as an endorsement of the contents by NASSCOM in any manner; and if you chose to access these articles/blogs , you do so at your own risk.


images
Dhiraj Sharma
Principal Analyst

© Copyright nasscom. All Rights Reserved.